Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
temozolomide + metformin
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination therapy consisting of temozolomide (TMZ), an alkylating agent that damages DNA in cancer cells, and metformin (MET), an anti-diabetic medication. This combination has shown synergistic effects in treating glioblastoma multiforme (GBM) by inhibiting proliferation and inducing apoptosis in both glioma cells and glioma stem cells. The combination works through multiple mechanisms including inhibition of AKT-mTOR signaling pathway, activation of AMP-activated protein kinase (AMPK), and down-regulation of SOX2 expression in TMZ-resistant cells. This combination is particularly valuable because it may overcome TMZ resistance, which is common in GBM patients.
- Other names
- metformin hydrochloride + temozolomide1,1-dimethylbiguanide hydrochloride + temozolomide
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)DNAND1 (Mitochondrial electron transport chain complex I)
Beyond the preview
Go deeper on temozolomide + metformin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on temozolomide + metformin.